Detailed explanation of the recommended usage and dosage in the instructions for Ivosidenib

Ivosidenib is an oral targeted drug mainly used to treat patients with relapsed or refractory acute myeloid leukemia (AML) who carry IDH1 gene mutations. According to the instructions, the standard dose of ivonib is 500 mg orally per day, and it is recommended to take it continuously until the disease progresses or intolerable side effects occur. There is no need to take the medicine with food, but the patient can choose to take it on an empty stomach or after a meal according to the patient's habits.

During the medication process, patients should take ivonib at a fixed time every day to ensure stable blood concentration and maximize the efficacy. If the patient misses a dose, it should be taken as soon as possible, but if the next dose is close, the missed dose should be skipped to avoid overdose. Do not increase the dose or frequency on your own to avoid aggravation of toxic side effects.

For patients with hepatic impairment, the instructions suggest that patients with mild or moderate hepatic impairment can take it at regular doses, while patients with severe hepatic impairment need to use it with caution and closely monitor liver function indicators. If serious adverse reactions occur, such as QT interval prolongation or hepatotoxicity, the medication should be suspended and related treatments should be carried out. After the symptoms are relieved, the medication can be resumed or the dosage adjusted as appropriate.

In short, the usage and dosage of ivonib is based on 500mg per day, emphasizing long-term continuous use, and individualized adjustments should be based on the patient's specific situation and adverse reaction management. Patients need to regularly review their blood and liver function while taking the medication, and take medication as directed by their doctor to ensure safety and efficacy.

Reference materials:https://www.drugs.com